Background
Materials and methods
Study population
Clinical characteristics
-
SUVmax tumour-to-background ratio (SUVmax TBR) = SUVmax primary tumour/SUVmax psoas major muscle
-
SUVmax liver-to-background ratio (SUVmax LBR) = SUVmax liver/SUVmax psoas major muscle
-
SUVmax tumour-to-liver ratio (SUVmax TLR) = (SUVmax primary tumour)/(SUVmax liver)
Statistical analysis
Results
Study population
Characteristic | No CYP3A4 (%) | CYP3A4 (%) | p value |
---|---|---|---|
Sex | 1.000** | ||
Male | 37 (74.0) | 15 (75.0) | |
Female | 13 (26.0) | 5 (25.0) | |
Age (years)† | 63.8 ± 9.4 | 68.0 ± 8.8 | 0.085# |
BMI (kg/m2)† | 27.2 ± 3.9 | 28.9 ± 5.4 | 0.202# |
Ki-67 value (%)* | 2.0 (1.0–6.7) | 3.0 (1.0–17.0) | 0.388¶ |
Primary tumour location | 0.760** | ||
Pancreas | 28 (59.6) | 7 (35.0) | |
Small bowel | 16 (34.0) | 3 (15.0) | |
Rectum | 1 (2.1) | 0 (0) | |
Stomach | 1 (2.1) | 1 (5.0) | |
Unknown location | 1 (2.1) | 0 (0) | |
No tumour | 3 (6.4) | 9 (45.0) | |
Primary tumour resection | 1.000** | ||
Resected | 4 (8.5) | 1 (9.1) | |
Not resected | 43 (91.5) | 10 (90.9) | |
WHO NETs grade | 0.134** | ||
I | 24 (52.1) | 3 (27.3) | |
II | 23 (47.9) | 5 (45.5) | |
III | 0 (0) | 1 (9.1) | |
Unknown | 0 (0) | 2 (18.2) | |
Tumour stage | 0.353** | ||
I | 5 (10.6) | 0 (0) | |
II | 14 (29.8) | 3 (27.3) | |
III | 10 (21.3) | 3 (27.3) | |
IV | 2 (4.3) | 2 (18.2) | |
Unknown | 16 (34.0) | 3 (27.3) | |
Metastasis | 0.181** | ||
Yes | 32 (68.1) | 5 (45.5) | |
No | 15 (31.9) | 6 (54.5) | |
PET/CT | 0.359** | ||
Initial | 36 (72.0) | 3 (15.0) | |
Follow-up | 14 (28.0) | 17 (85.0) | |
PET/CT scanner | 1.000** | ||
Philips | 41 (82.0) | 17 (85.0) | |
Siemens | 9 (18.0) | 3 (15.0) | |
Activity (MBq/kg)† | 1.4 ± 0.2 | 1.4 ± 0.3 | 0.291# |
Peptide (ng/kg)† | 158 ± 66 | 156 ± 91 | 0.954# |
[177Lu]Lu-DOTA-TATE therapy | 1.000** | ||
Yes | 0 (0) | 0 (0) | |
No | 47 (100) | 11 (100) | |
CYP3A4 inhibitors | NA | ||
Verapamil | NA | 10 | |
Amiodarone | NA | 7 | |
Clarithromycin | NA | 2 | |
Ketoconazole | NA | 1 |
[68Ga]Ga-DOTA-TATE uptake
Characteristic | No CYP3A4* | CYP3A4* | p value† |
---|---|---|---|
SUVmax TBR‡ | 26.6, 18.6–34.1 n = 43 | 28.1, 16.3–60.0 n = 10 | 0.838 |
SUVmax LBR | 8.9, 7.2–11.9 n = 50 | 9.2, 7.0–14.1 n = 20 | 0.550 |
SUVmax TLR‡ | 3.0, 1.8–4.7 n = 43 | 3.4, 1.7–5.7 n = 10 | 0.733 |